---
document_datetime: 2024-12-16 15:41:05
document_pages: 17
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/hyrimoz-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: hyrimoz-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 8.5785156
conversion_datetime: 2025-12-21 12:12:44.574135
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Hyrimoz

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| WS/2764/G            | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and | 12/12/2024                          |                                             | SmPC, Labelling and PL           |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | Veterinary Medicinal Products - Other variation C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                     |            |     |                                                                                                                                                               |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2630   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                             | 11/04/2024 | n/a |                                                                                                                                                               |
| WS/2675   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.e.3.z - Change in test procedure for the immediate packaging of the finished product - Other variation                                                                                        | 04/04/2024 | n/a |                                                                                                                                                               |
| WS/2591/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.13: Submission of the final report from study RABBIT. This is a German registry for the long-term observation of therapy with biologics in adult patients with rheumatoid arthritis. | 11/01/2024 | n/a | The safety profile of adalimumab is well characterised, and no new safety issues were identified in the 3 category 3 studies. No SmPC updates were necessary. |

<div style=\"page-break-after: always\"></div>

|             | C.I.13: Submission of the final report from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). This is a registry to investigate the long-term safety outcomes of psoriasis patients treated with biologic therapy. C.I.13: Submission of the final report from the Inflammatory Bowel Disease Registry (UK-IBD). This registry was used to identify adverse reactions to Hyrimoz in a cohort of inflammatory bowel disease patients managed in a real-world setting. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission   |            |            |              |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------|
| N/0050      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 18/12/2023 | 19/07/2024 | PL           |
| IB/0048     | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 02/10/2023 | n/a        |              |
| IAIN/0047/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 19/09/2023 | 19/07/2024 | Annex II and |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| A.5.b - Administrative change and/or address of a manufacturer/importer finished product, including (excluding manufacturer B.II.b.2.c.1 - Change to arrangements and quality Replacement or addition responsible for importation Not including batch control/testing A.4 - Administrative change and/or address of a manufacturer or supplier of the AS, starting intermediate used in the manufacturer of a novel A.4 - Administrative change and/or address of a manufacturer or supplier of the AS, starting intermediate used in the manufacturer of a novel A.4 - Administrative change and/or address of a manufacturer or supplier of the AS, starting intermediate used in the manufacturer of a novel A.5.b - Administrative change and/or address of a manufacturer/importer finished product, including (excluding manufacturer A.5.b - Administrative change and/or address of a manufacturer/importer finished product, including   | PL   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|

<div style=\"page-break-after: always\"></div>

| PSUSA/10783 /202212   | Periodic Safety Update EU Single assessment - adalimumab                                                                                                                                                                                                                                                                                           | 31/08/2023   | n/a        |                        | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| IB/0045               | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                | 07/08/2023   | 19/07/2024 | SmPC, Labelling and PL |                                     |
| IB/0044/G             | This was an application for a group of variations. B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                           | 26/07/2023   | n/a        |                        |                                     |
| IB/0043               | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                         | 13/06/2023   | n/a        |                        |                                     |
| IG/1628/G             | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging container without a complete deletion of a strength or pharmaceutical form | 02/06/2023   | n/a        |                        |                                     |
| IB/0041               | B.II.e.3.b - Change in test procedure for the immediate packaging of the finished product - Other                                                                                                                                                                                                                                                  | 28/04/2023   | n/a        |                        |                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|          | changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                                  |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| X/0036/G | This was an application for a group of variations. Annex I_2.(c) Change or addition of a new strength/potency B.II.a.5 - Change in concentration of a single-dose, total use parenteral product, where the amount of AS per unit dose (i.e. the strength) remains the same B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate A.7 - Administrative change - Deletion of manufacturing sites B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits | 26/01/2023 | 31/03/2023 | SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| variation B.I.b.2.d - Change in test starting material/reagent/intermediate change to or replacement biological/immunological/immunochemical method or a method using biological AS B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.II.e.5.a.1 - Change product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in the tablets, ampoules, etc.)   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes   |            |            |             |                                                                                                                                                                                                                                                                       |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1601 | B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits                                                                                                                                                                                                                                                              | 22/03/2023 | n/a        |             |                                                                                                                                                                                                                                                                       |
| R/0037  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                 | 15/12/2022 | 15/02/2023 | SmPC and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Hyrimoz in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0038 | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                            | 18/10/2022 | n/a        |             |                                                                                                                                                                                                                                                                       |
| IG/1480 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                        | 02/02/2022 | n/a        |             |                                                                                                                                                                                                                                                                       |
| IB/0034 | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                           | 03/11/2021 | n/a        |             |                                                                                                                                                                                                                                                                       |
| IB/0033 | C.I.2.a - Change in the SPC, Labelling or PL of a                                                                                                                                                                                                                                                                                                                                                       | 01/10/2021 | 22/10/2021 | SmPC and PL |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                        |                                                                                                                                                                                           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1908/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method | 22/07/2021 | n/a        |                        |                                                                                                                                                                                           |
| IB/0031   | Type IB (B.II.f.1.d) - Removal of the 'do not shake' warning from the PI. Article 61(3) notifications - Update of local representatives list included in the patient information leaflet. B.II.f.1.d - Stability of FP - Change in storage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 08/06/2021 | 22/10/2021 | SmPC, Labelling and PL | Type IB (B.II.f.1.d) - Removal of the 'do not shake' warning from the PI. Article 61(3) notifications - Update of local representatives list included in the patient information leaflet. |

<div style=\"page-break-after: always\"></div>

|                     | conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| IG/1400/G           | This was an application for a group of variations. B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier | 31/05/2021 | n/a        |             |                                   |
| WS/2025             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                          | 09/04/2021 | n/a        |             |                                   |
| IG/1380             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                      | 26/03/2021 | 22/10/2021 | SmPC and PL |                                   |
| IB/0027             | B.IV.1.z - Change of a measuring or administration device - Other variation                                                                                                                                                                                                                                                                                                                                         | 11/11/2020 | n/a        |             |                                   |
| IG/1290             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                      | 05/10/2020 | 09/03/2021 | SmPC and PL |                                   |
| PSUSA/10783 /201912 | Periodic Safety Update EU Single assessment - adalimumab                                                                                                                                                                                                                                                                                                                                                            | 03/09/2020 | n/a        |             | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IG/1288   | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of                                                                                                                                                                                                                                                                                                                                           | 27/08/2020   | n/a        |                                  | specification limits   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|------------------------|
| IB/0023   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                         | 20/07/2020   | 09/03/2021 | SmPC and PL                      |                        |
| IB/0021/G | This was an application for a group of variations. B.I.a.3.e - Change in batch size (including batch size ranges) of AS or intermediate - The scale for a biological/immunological AS is increased/decreased without process change (e.g. duplication of line) B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 17/06/2020   | n/a        |                                  |                        |
| IA/0022   | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                              | 08/06/2020   | n/a        |                                  |                        |
| X/0013    | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                  | 30/01/2020   | 27/03/2020 | SmPC, Annex II, Labelling and PL |                        |

<div style=\"page-break-after: always\"></div>

| IG/1190/G   | This was an application for a group of variations. B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished                                                                                                             | 26/03/2020   | n/a        |      |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|
| WS/1765     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 05/03/2020   | 09/03/2021 | SmPC |
| IB/0017     | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                                                                                                                                                                                    | 10/12/2019   | n/a        |      |
| IA/0016/G   | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the                                                    | 26/09/2019   | n/a        |      |

<div style=\"page-break-after: always\"></div>

|                     | finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |           |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|-----------------------------------|
| WS/1643/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits | 19/09/2019 | n/a        |           |                                   |
| N/0015              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                         | 16/08/2019 | 23/09/2019 | Labelling |                                   |
| IA/0014             | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                       | 31/07/2019 | n/a        |           |                                   |
| IB/0011             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                           | 25/07/2019 | 23/09/2019 | Annex II  |                                   |
| PSUSA/10589 /201812 | Periodic Safety Update EU Single assessment - adalimumab (biosimilars)                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 11/07/2019 | n/a        |           | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IA/0010   | - Change in the manufacturing process of finished or intermediate product - Minor change the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11/06/2019   | n/a        |                                  | B.II.b.3.a the in   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|---------------------|
| WS/1565   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by                                                                                                                                                                                                                                                                                                                                          | 28/03/2019   | 23/09/2019 | SmPC, Annex II, Labelling and PL | the MAH             |
| IB/0007/G | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its | 21/03/2019   | n/a        |                                  |                     |

<div style=\"page-break-after: always\"></div>

|           | test method - Change in test procedure for AS or material/reagent/intermediate - Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |      | corresponding B.I.b.2.z starting variation   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------|
| IB/0006   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 19/02/2019 | 23/09/2019 | SmPC |                                              |
| WS/1479/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products | 17/01/2019 | n/a        |      |                                              |

<div style=\"page-break-after: always\"></div>

| IAIN/0005/G   | for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                     | 20/12/2018   | n/a        |                                  | This was an application   |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|---------------------------|
| IB/0004       | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 27/11/2018   | n/a        |                                  |                           |
| IAIN/0003     | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14/11/2018   | n/a        |                                  |                           |
| IB/0002/G     | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 15/10/2018   | 23/09/2019 | SmPC, Annex II, Labelling and PL |                           |